PAS
RLMD icon

Point72 Asia (Singapore)’s Relmada Therapeutics RLMD Stock Holding History

Point72 Asia (Singapore)’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-49,882
Closed -$232K – 1430
2024
Q1 		$232K Buy
+49,882
New +$240K 0.06% 368

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Point72 Asia (Singapore)'s RLMD Position: Q2 2024 in Review

Point72 Asia (Singapore) sold out of Relmada Therapeutics (RLMD) in Q2 2024, closing a stake of 49,882 shares — an estimated $232K sold.

Point72 Asia (Singapore) first reported a position in RLMD in Q1 2024 and held it in 1 quarter. The position peaked at $232K in Q1 2024. 79 funds tracked by Wall St. Rank hold RLMD as of Q2 2024.

  • Point72 Asia (Singapore) reported no remaining Relmada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 49,882 Relmada Therapeutics shares in Q2 2024, an estimated $232K.
  • Point72 Asia (Singapore) first reported a position in Relmada Therapeutics in Q1 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Relmada Therapeutics position peaked at $232K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2024, filed 14 Aug 2024.